Cargando…

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications

Fibroblast growth factors (FGFs) and their receptors (FGFRs) are transmembrane growth factor receptors with wide tissue distribution. FGF/FGFR signaling is involved in neoplastic behavior and also development, differentiation, growth, and survival. FGFR germline mutations (activating) can cause skel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Helsten, Teresa, Schwaederle, Maria, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573649/ https://www.ncbi.nlm.nih.gov/pubmed/26224133 http://dx.doi.org/10.1007/s10555-015-9579-8

Ejemplares similares

Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics
por: Parish, A, et al.
Publicado: (2015)

Genomic landscape of salivary gland tumors
por: Kato, Shumei, et al.
Publicado: (2015)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

HER2 expression status in diverse cancers: review of results from 37,992 patients
por: Yan, Min, et al.
Publicado: (2015)

A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for Inhibition of the IGF-1R signal
por: Janku, Filip, et al.
Publicado: (2013)

NF2/Merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations
por: Schroeder, Rebecca Dunbar, et al.
Publicado: (2013)

Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology
por: Patel, Sandip P., et al.
Publicado: (2015)

An appraisal of drug development timelines in the Era of precision oncology
por: Jardim, Denis Leonardo, et al.
Publicado: (2016)

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
por: Khemlina, Galina, et al.
Publicado: (2017)

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
por: Adashek, Jacob J., et al.
Publicado: (2020)

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients
por: Heestand, Gregory M., et al.
Publicado: (2017)

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [(18)F] fluorodeoxyglucose ((18)F-FDG PET)
por: Chang, Geraldine H., et al.
Publicado: (2018)

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types
por: Schwaederle, Maria, et al.
Publicado: (2015)

Molecular landscape of pancreatic cancer: implications for current clinical trials
por: Heestand, Gregory M., et al.
Publicado: (2015)

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
por: Shayeb, Akram Mesleh, et al.
Publicado: (2023)

Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications
por: Jiang, Yunyun, et al.
Publicado: (2013)

Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications
por: Cohen, Philip R., et al.
Publicado: (2015)

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response
por: Persha, Hanna E., et al.
Publicado: (2022)

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics
por: Kato, Shumei, et al.
Publicado: (2015)

Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia
por: Molica, S, et al.
Publicado: (2002)

Fibroblast Growth Factor Receptor Signaling in Skin Cancers
por: Czyz, Malgorzata
Publicado: (2019)

Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden
por: Boichard, Amélie, et al.
Publicado: (2021)

Cyclin alterations in diverse cancers: outcome and co-amplification network
por: Schwaederlé, Maria, et al.
Publicado: (2014)

Fibroblast Growth Factor 2 and Its Receptors in Bone Biology and Disease
por: Coffin, J Douglas, et al.
Publicado: (2018)

Androgen receptors beyond prostate cancer: an old marker as a new target
por: Munoz, Javier, et al.
Publicado: (2014)

Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer
por: Lei, Haipeng, et al.
Publicado: (2017)

Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling
por: Szybowska, Patrycja, et al.
Publicado: (2021)

Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa
por: Piazzi, G, et al.
Publicado: (2006)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

Telomerase Reverse Transcriptase Promoter Alterations Across Cancer Types as Detected by Next-Generation Sequencing: A Clinical and Molecular Analysis of 423 Patients
por: Schwaederle, Maria, et al.
Publicado: (2017)

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
por: Daud, Adil, et al.
Publicado: (2017)

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer
por: Schwaederle, Maria, et al.
Publicado: (2015)

Heparin-Binding Epidermal Growth Factor-like Growth Factor/Diphtheria Toxin Receptor in Normal and Neoplastic Hematopoiesis
por: Vinante, Fabrizio, et al.
Publicado: (2013)

Fool’s gold, lost treasures, and the randomized clinical trial
por: Stewart, David J, et al.
Publicado: (2013)

Tyrosine kinase signalling in breast cancer: Fibroblast growth factors and their receptors
por: Dickson, Clive, et al.
Publicado: (2000)

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
por: André, Fabrice, et al.
Publicado: (2015)

Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
por: Ferguson, Harriet R., et al.
Publicado: (2021)

Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer
por: Francavilla, Chiara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jer678kit96jgs5bp20sb4od7a